|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Sir
Andrew Witty
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
406.772
(personal contribution)
|
||
|
£15.66
|
406.759
(personal contribution)
|
||
|
£15.66
|
203.865
(personal contribution)
|
||
|
£15.66
|
203.865
(personal contribution)
|
||
|
£15.66
|
510.713
(personal contribution)
|
||
|
£15.66
|
406.772
(matching shares)
|
||
|
£15.66
|
406.759
(matching shares)
|
||
|
£15.66
|
203.865
(matching shares)
|
||
|
£15.66
|
203.865
(matching shares)
|
||
|
£15.66
|
510.713
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
3,463.948
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Ms E
Walmsley
|
|
|
b)
|
Position/status
|
CEO
Designate
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
89.065
(personal contribution)
|
||
|
£15.66
|
89.065
(personal contribution)
|
||
|
£15.66
|
71.015
(personal contribution)
|
||
|
£15.66
|
71.015
(personal contribution)
|
||
|
£15.66
|
175.863
(personal contribution)
|
||
|
£15.66
|
175.850
(personal contribution)
|
||
|
£15.66
|
89.065
(matching shares)
|
||
|
£15.66
|
89.065
(matching shares)
|
||
|
£15.66
|
71.015
(matching shares)
|
||
|
£15.66
|
71.015
(matching shares)
|
||
|
£15.66
|
175.863
(matching shares)
|
||
|
£15.66
|
175.850
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,343.746
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr R G
Connor
|
|
|
b)
|
Position/status
|
President,
Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
79.620
(personal contribution)
|
||
|
£15.66
|
79.607
(personal contribution)
|
||
|
£15.66
|
52.007
(personal contribution)
|
||
|
£15.66
|
52.007
(personal contribution)
|
||
|
£15.66
|
119.484
(personal contribution)
|
||
|
£15.66
|
79.620
(matching shares)
|
||
|
£15.66
|
79.607
(matching shares)
|
||
|
£15.66
|
52.007
(matching shares)
|
||
|
£15.66
|
52.007
(matching shares)
|
||
|
£15.66
|
119.484
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
765.45
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr S
Dingemans
|
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
192.213
(personal contribution)
|
||
|
£15.66
|
76.874
(personal contribution)
|
||
|
£15.66
|
99.193
(personal contribution)
|
||
|
£15.66
|
99.180
(personal contribution)
|
||
|
£15.66
|
232.242
(personal contribution)
|
||
|
£15.66
|
232.229
(personal contribution)
|
||
|
£15.66
|
192.213
(matching shares)
|
||
|
£15.66
|
76.874
(matching shares)
|
||
|
£15.66
|
99.193
(matching shares)
|
||
|
£15.66
|
99.180
(matching shares)
|
||
|
£15.66
|
232.242
(matching shares)
|
||
|
£15.66
|
232.229
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,863.862
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr N
Hirons
|
|
|
b)
|
Position/status
|
SVP,
Global Ethics & Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
36.414
(personal contribution)
|
||
|
£15.66
|
36.414
(personal contribution)
|
||
|
£15.66
|
85.869
(personal contribution)
|
||
|
£15.66
|
85.869
(personal contribution)
|
||
|
£15.66
|
36.414
(matching shares)
|
||
|
£15.66
|
36.414
(matching shares)
|
||
|
£15.66
|
85.869
(matching shares)
|
||
|
£15.66
|
85.869
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
489.132
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr S A
Hussain
|
|
|
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
116.783
(personal contribution)
|
||
|
£15.66
|
171.654
(personal contribution)
|
||
|
£15.66
|
202.916
(personal contribution)
|
||
|
£15.66
|
202.916
(personal contribution)
|
||
|
£15.66
|
116.783
(matching shares)
|
||
|
£15.66
|
171.654
(matching shares)
|
||
|
£15.66
|
202.916
(matching shares)
|
||
|
£15.66
|
202.916
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,388.538
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr D S
Redfern
|
|
|
b)
|
Position/status
|
Chief
Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
72.618
(personal contribution)
|
||
|
£15.66
|
72.605
(personal contribution)
|
||
|
£15.66
|
58.351
(personal contribution)
|
||
|
£15.66
|
58.351
(personal contribution)
|
||
|
£15.66
|
109.284
(personal contribution)
|
||
|
£15.66
|
109.284
(personal contribution)
|
||
|
£15.66
|
72.618
(matching shares)
|
||
|
£15.66
|
72.605
(matching shares)
|
||
|
£15.66
|
58.351
(matching shares)
|
||
|
£15.66
|
58.351
(matching shares)
|
||
|
£15.66
|
109.284
(matching shares)
|
||
|
£15.66
|
109.284
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
960.986
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Dr M M
Slaoui
|
|
|
b)
|
Position/status
|
Chairman,
Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 12 January 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$39.01
|
125.340
(personal contribution)
|
||
|
$39.01
|
125.327
(personal contribution)
|
||
|
$39.01
|
78.047
(personal contribution)
|
||
|
$39.01
|
78.047
(personal contribution)
|
||
|
$39.01
|
128.475
(personal contribution)
|
||
|
$39.01
|
128.475
(personal contribution)
|
||
|
$39.01
|
125.340
(matching shares)
|
||
|
$39.01
|
125.327
(matching shares)
|
||
|
$39.01
|
78.047
(matching shares)
|
||
|
$39.01
|
78.047
(matching shares)
|
||
|
$39.01
|
128.475
(matching shares)
|
||
|
$39.01
|
128.475
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,327.422
$39.01
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Ms C
Thomas
|
|
|
b)
|
Position/status
|
SVP,
Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
90.103
(personal contribution)
|
||
|
£15.66
|
78.542
(personal contribution)
|
||
|
£15.66
|
78.530
(personal contribution)
|
||
|
£15.66
|
159.879
(personal contribution)
|
||
|
£15.66
|
159.879
(personal contribution)
|
||
|
£15.66
|
90.103
(matching shares)
|
||
|
£15.66
|
78.542
(matching shares)
|
||
|
£15.66
|
78.530
(matching shares)
|
||
|
£15.66
|
159.879
(matching shares)
|
||
|
£15.66
|
159.879
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,133.866
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr P C
Thomson
|
|
|
b)
|
Position/status
|
SVP,
Communications & Government Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
54.266
(personal contribution)
|
||
|
£15.66
|
53.347
(personal contribution)
|
||
|
£15.66
|
97.819
(personal contribution)
|
||
|
£15.66
|
54.266
(matching shares)
|
||
|
£15.66
|
53.347
(matching shares)
|
||
|
£15.66
|
97.819
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
410.864
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Mr D E
Troy
|
|
|
b)
|
Position/status
|
SVP
& General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 12 January 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$39.01
|
50.726
(personal contribution)
|
||
|
$39.01
|
50.726
(personal contribution)
|
||
|
$39.01
|
40.386
(personal contribution)
|
||
|
$39.01
|
40.386
(personal contribution)
|
||
|
$39.01
|
90.932
(personal contribution)
|
||
|
$39.01
|
90.932
(personal contribution)
|
||
|
$39.01
|
50.726
(matching shares)
|
||
|
$39.01
|
50.726
(matching shares)
|
||
|
$39.01
|
40.386
(matching shares)
|
||
|
$39.01
|
40.386
(matching shares)
|
||
|
$39.01
|
90.932
(matching shares)
|
||
|
$39.01
|
90.932
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
728.176
$39.01
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||
|
a)
|
Name
|
Dr P J
T Vallance
|
|
|
b)
|
Position/status
|
President,
Pharmaceuticals R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2017 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.66
|
161.014
(personal contribution)
|
||
|
£15.66
|
161.001
(personal contribution)
|
||
|
£15.66
|
115.614
(personal contribution)
|
||
|
£15.66
|
115.614
(personal contribution)
|
||
|
£15.66
|
188.068
(personal contribution)
|
||
|
£15.66
|
188.068
(personal contribution)
|
||
|
£15.66
|
161.014
(matching shares)
|
||
|
£15.66
|
161.001
(matching shares)
|
||
|
£15.66
|
115.614
(matching shares)
|
||
|
£15.66
|
115.614
(matching shares)
|
||
|
£15.66
|
188.068
(matching shares)
|
||
|
£15.66
|
188.068
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,858.758
£15.66
|
|
|
e)
|
Date of
the transaction
|
2017-01-12
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
16, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE-
-------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|